SGMT on Nasdaq

Sagimet Biosciences Inc.

American pharmaceutical preparations company based in San Mateo.

Price unavailable

Last updated Oct 18, 2026.

Overview

-$51.0MNet income, fiscal 2025²

Compare with Oramed Pharmaceuticals, Cocrystal Pharma, Inc. or Lipocine Inc., or pick any stock.

TickerSGMT on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersSan Mateo, United States
Incorporated inDE³
Business address950 Tower Lane, Ste 1500, Foster City, Ca 94404³
Filer category, Emerging growth company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-1537.0%Operating margin⁴

-1393.8%Net margin⁴

-30.6%Return on equity²

Where the money goes

Where each dollar of revenue went, fiscal 2023

Research and development

Research and development100¢$19.8M

Out of $2.0M in revenue.⁴ The company lost money this year.

Financial statements

Operating income⁵⁴-$30.7M in 2023−1% since 2022

Net income⁵⁴-$27.9M in 2023−9% since 2022

Every line of the income statement as filed: the last 2 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31
Research and development expenses	$39.1M	$38.4M
General and administrative expenses	$17.8M	$16.0M
Total operating expenses	$56.9M	$54.5M
Loss from operations	-$56.9M	-$54.5M
Interest income and other, net	$5.9M	$8.9M
Total other income	$5.9M	$8.9M
Net loss	-$51.0M	-$45.6M
Net loss per share, basic (in dollars per share)	-$1.58	-$1.45
Net loss per share, diluted (in dollars per share)	-$1.58	-$1.45
Weighted-average shares outstanding, basic (in shares)	32.3M shares	31.4M shares
Weighted-average shares outstanding, diluted (in shares)	32.3M shares	31.4M shares
Net unrealized gain (loss) on marketable securities	-$110.0K	$200.0K
Total comprehensive loss	-$51.1M	-$45.4M

Total assets⁵⁴$96.7M in 2023+193% since 2022

Total liabilities⁵$5.7M in 2023+5% since 2022

Shareholders’ equity⁵⁴²$91.1M in 2023

Cash⁵⁴$75.1M in 2023+32% since 2021

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.²

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$35.0M	$75.8M
Short-term marketable securities	$78.1M	$75.4M
Prepaid expenses and other current assets	$3.3M	$1.5M
Total current assets	$116.4M	$152.8M
Long-term marketable securities	$0	$7.4M
Operating lease right-of-use assets	$78.0K	$77.0K
Total assets	$116.5M	$160.3M
Accounts payable	$1.3M	$1.4M
Accrued expenses and other current liabilities	$3.7M	$3.0M
Operating lease liabilities	$78.0K	$78.0K
Total current liabilities	$5.1M	$4.5M
Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024	$0	$0
Additional paid-in capital	$457.6M	$450.9M
Accumulated deficit	-$346.3M	-$295.3M
Accumulated other comprehensive income	$120.0K	$230.0K
Total stockholders' equity	$111.4M	$155.8M	$91.1M
Total liabilities and stockholders' equity	$116.5M	$160.3M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$35.0M	$75.8M
Short-term marketable securities	$78.1M	$75.4M
Prepaid expenses and other current assets	$3.3M	$1.5M
Total current assets	$116.4M	$152.8M
Long-term marketable securities	$0	$7.4M
Operating lease right-of-use assets	$78.0K	$77.0K
Total assets	$116.5M	$160.3M
Accounts payable	$1.3M	$1.4M
Accrued expenses and other current liabilities	$3.7M	$3.0M
Operating lease liabilities	$78.0K	$78.0K
Total current liabilities	$5.1M	$4.5M
Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024	$0	$0
Additional paid-in capital	$457.6M	$450.9M
Accumulated deficit	-$346.3M	-$295.3M
Accumulated other comprehensive income	$120.0K	$230.0K
Total stockholders' equity	$111.4M	$155.8M	$91.1M
Total liabilities and stockholders' equity	$116.5M	$160.3M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares

Cash from operations⁵⁴-$23.8M in 2023−3% since 2022

Every line of the cash flow as filed: the last 2 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31
Net loss	-$51.0M	-$45.6M
Accretion of discount on marketable securities	-$389.0K	-$1.3M
Non-cash operating lease expense	$151.0K	$145.0K
Stock-based compensation expense	$6.4M	$5.3M
Write-off of deferred financing costs	$230.0K	$0
Prepaid expenses and other current assets	-$1.8M	-$5.0K
Accounts payable, accrued expenses and other current liabilities	$929.0K	-$907.0K
Operating lease liabilities	-$152.0K	-$136.0K
Net cash used in operating activities	-$45.6M	-$42.4M
Purchases of marketable securities	-$106.9M	-$108.1M
Sales and maturities of marketable securities	$111.4M	$46.4M
Net cash provided by (used in) investing activities	$4.6M	-$61.7M
Proceeds from sale of Series A common stock, net of issuance costs	$0	$105.8M
Payment of financing costs	$0	-$1.0M
Proceeds from exercise of stock options	$275.0K	$114.0K
Net cash provided by financing activities	$275.0K	$104.8M
Net (decrease) increase in cash and cash equivalents	-$40.8M	$701.0K
Right-of-use assets obtained in exchange for operating lease obligations	$152.0K	$149.0K
Deferred financing costs within accounts payable and accrued expenses	$9.0K	$0

Compare Sagimet Biosciences Inc. with another company

Leadership

Who has led Sagimet Biosciences Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

Chief operating officer

Anthony M. Rimac2023

2025

Chief executive officerDavid Happel Jul 13, 2023 to now¹⁰
ChairGeorge Kemble Sep 8, 2023 to now¹¹
PresidentDavid Happel Jul 13, 2023 to now¹⁰
Chief financial officerThierry Chauche May 8, 2024 to now¹²
Chief financial officerDennis Hom Jul 13, 2023 to Jul 20, 2023¹³
Chief operating officerAnthony M. Rimac Jul 13, 2023 to Jul 20, 2023¹⁴

Board members and other officers (16)

Chief Medical OfficerAndreas Grauer May 14, 2026 to now¹⁵
OfficerJoseph Oriti Feb 2, 2024 to Feb 2, 2024¹⁶
Chief Medical OfficerEduardo Bruno Martins Jul 20, 2023 to now¹⁷
Board memberPaul W. Hoelscher Apr 3, 2024 to now¹⁸
Board memberTimothy P. Walbert Apr 3, 2024 to now¹⁹
Board memberAnne M. Phillips Aug 5, 2024 to now²⁰
Board memberJennifer Jarrett Aug 5, 2024 to now²¹
Board memberBeth C. Seidenberg Jul 13, 2023 to now²²
Board memberDavid Happel Jul 13, 2023 to now¹⁰
Board memberEduardo Bruno Martins Jul 13, 2023 to Jul 13, 2023²³
Board memberElizabeth A. Grammer Jul 13, 2023 to now²⁴
Board memberGeorge Kemble Jul 13, 2023 to now²⁵
Board memberJinzi Jason Wu Jul 13, 2023 to Jul 20, 2023²⁶
Board memberMerdad Parsey Jul 13, 2023 to Jun 7, 2024²⁷
Board memberRichard J. Rodgers Jul 13, 2023 to Jul 20, 2023²⁸
General counselElizabeth Rozek Jul 13, 2023 to now²⁹

Former names

3-V Biosciences, Inc.May 8, 2007 to Feb 25, 2019³

Timeline

Jul 13, 2023New chief executive David Happel becomes CEO¹⁰

Filings

249 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 53 major events, 100 insider forms, 24 large holders, 59 other. The latest 20:

Oct 7, 2026SCHEDULE 13G EDGAR
Oct 1, 20268-K EDGAR
Oct 1, 2026424B5 EDGAR
Sep 30, 20268-K EDGAR
Sep 30, 2026424B3 EDGAR
Aug 17, 20264 EDGAR
Aug 14, 2026144 EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 13, 20268-K EDGAR
Aug 12, 20264 EDGAR
Aug 11, 2026144 EDGAR
Aug 11, 20268-K EDGAR
Aug 11, 202610-Q EDGAR
Jul 30, 2026SCHEDULE 13G EDGAR
Jul 22, 20264 EDGAR
Jul 22, 20264 EDGAR
Jul 22, 20264 EDGAR
Jul 21, 20268-K EDGAR
Jul 20, 2026144 EDGAR
Jun 15, 20264 OWNERSHIP DOCUMENT EDGAR

The 249 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 24 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
BlackRock, Inc.	6,575,788	$50.8M	0.0%	+5,775,845
Balyasny Asset Management L.P.	3,626,113	$28.0M	0.1%	New
Woodline Partners LP	3,000,652	$23.2M	0.1%	+1,999,709
Silverarc Capital Management, LLC	2,927,698	$22.6M	2.5%	New
Vanguard Capital Management LLC	2,566,272	$19.8M	0.0%	+1,467,353
Bvf Inc/il	2,500,000	$19.3M	0.5%	New
Caligan Partners LP	2,500,000	$19.3M	0.9%	New
Affinity Asset Advisors, LLC	2,497,864	$19.3M	1.0%	+1,629,844
Federated Hermes, Inc.	2,086,715	$16.1M	0.0%	+2,085,934
Great Point Partners LLC	2,029,933	$15.7M	3.7%	New
State Street Corp	1,995,092	$15.4M	0.0%	+1,866,304
Saturn V Capital Management LP	1,479,918	$11.4M	1.6%	New
Geode Capital Management, LLC	1,444,019	$11.2M	0.0%	+1,134,497
Blue Owl Capital Holdings LP	1,260,544	$9.7M	1.5%	+926,667
Baker Bros. Advisors LP	952,996	$7.4M	0.0%	No change
Millennium Management LLC	937,025	$7.2M	0.0%	+74,722
Aberdeen Group plc	847,700	$6.6M	0.0%	New
Goldman Sachs Group Inc	759,086	$5.9M	0.0%	+589,827
Hhlr Advisors, Ltd.	724,800	$5.6M	0.7%	No change
Ameriprise Financial Inc	581,217	$4.5M	0.0%	New
Vestal Point Capital, LP	535,452	$4.1M	0.1%	New
Northern Trust Corp	468,385	$3.6M	0.0%	+412,874
Boothbay Fund Management, LLC	464,095	$3.6M	0.1%	New
ADAR1 Capital Management, LLC	437,500	$3.4M	0.2%	New
Farallon Capital Management, L.l.c.	415,000	$3.2M	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSagimet Biosciences Inc. filings on SEC EDGAR
2
SEC EDGARSagimet Biosciences Inc. 10-K for fiscal 2025
3
SEC EDGARSagimet Biosciences Inc. filings on SEC EDGAR
4
SEC EDGARSagimet Biosciences Inc. 10-K for fiscal 2023
5
SEC EDGARSagimet Biosciences Inc. 10-K for fiscal 2022
6
SEC EDGARSagimet Biosciences Inc. 10-Q for fiscal 2025
7
SEC EDGARSagimet Biosciences Inc. 10-Q for fiscal 2025
8
SEC EDGARSagimet Biosciences Inc. 10-Q for fiscal 2026
9
SEC EDGARSagimet Biosciences Inc. 10-Q for fiscal 2025
10
SEC EDGARDavid Happel, Chief executive officer
11
SEC EDGARGeorge Kemble, Chair
12
SEC EDGARThierry Chauche, Chief financial officer
13
SEC EDGARDennis Hom, Chief financial officer
14
SEC EDGARAnthony M. Rimac, Chief operating officer
15
SEC EDGARAndreas Grauer, Chief Medical Officer
16
SEC EDGARJoseph Oriti, Officer
17
SEC EDGAREduardo Bruno Martins, Chief Medical Officer
18
SEC EDGARPaul W. Hoelscher, Board member
19
SEC EDGARTimothy P. Walbert, Board member
20
SEC EDGARAnne M. Phillips, Board member
21
SEC EDGARJennifer Jarrett, Board member
22
SEC EDGARBeth C. Seidenberg, Board member
23
SEC EDGAREduardo Bruno Martins, Board member
24
SEC EDGARElizabeth A. Grammer, Board member
25
SEC EDGARGeorge Kemble, Board member
26
SEC EDGARJinzi Jason Wu, Board member
27
SEC EDGARMerdad Parsey, Board member
28
SEC EDGARRichard J. Rodgers, Board member
29
SEC EDGARElizabeth Rozek, General counsel